Every Form 4 that Repare Therapeutics Inc. (RPTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RPTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RPTX filings page.
Repare Therapeutics Inc. saw its largest shareholders cashed out in a merger. Investment funds affiliated with BVF Partners, including Biotechnology Value Fund, Biotechnology Value Fund II and Biotechnology Value Trading Fund OS, reported the disposition of their Repare common shares on January 28, 2026 in connection with a completed acquisition by XenoTherapeutics Inc. Under the arrangement, each common share was exchanged for $2.20 in cash plus one contingent value right for potential additional cash payments, and the BVF-related entities now report holding zero Repare shares after the transaction.
Repare Therapeutics director Carol Schafer has exited her position in the company through a cash-and-rights buyout. On January 28, 2026, she disposed of 8,000 common shares and had 37,941 stock options cancelled under an Arrangement Agreement involving XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation.
Each common share was exchanged for $2.20 in cash plus one contingent value right (CVR). Each option was cancelled in return for $2.20 minus its exercise price per underlying share, plus one CVR per underlying share, effectively cashing out her remaining equity in connection with the acquisition of all Repare common shares.
Repare Therapeutics director Ann D. Rhoads reported the disposition of 4,000 common shares in connection with the company’s acquisition. On January 28, 2026, all of her shares were exchanged under an Arrangement Agreement with XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation.
Each Repare share was converted into $2.20 in cash plus one non‑transferable contingent value right (CVR), and Rhoads now reports owning zero Repare common shares following the transaction.
Repare Therapeutics Inc. director Civik Thomas reported the disposition of 7,500 common shares on January 28, 2026, reducing his reported holdings to zero. The Form 4 lists the transaction code as "D" for a non-derivative disposition.
According to the Arrangement Agreement dated November 14, 2025 among Repare Therapeutics, XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation, each Repare common share was acquired by the purchaser in exchange for $2.20 in cash per share plus one non-transferable contingent value right (CVR) per share.
Repare Therapeutics EVP and CFO Steve Forte reported the cancellation of his equity holdings following the company’s acquisition. On January 28, 2026, 56,786 common shares were disposed of, including shares from restricted stock units and the employee stock purchase plan, as part of an Arrangement Agreement.
Under this agreement, all issued and outstanding Repare common shares were acquired for $2.20 in cash per share plus one contingent value right (CVR). Several employee stock options to buy common shares, with various exercise prices and expirations, were also cancelled in exchange for $2.20 minus the option exercise price per underlying share plus one CVR per underlying share.
Repare Therapeutics SVP, Finance and CAO, Sandra Isabelle Barros Alves reported the cancellation of 31,622 common shares and two employee stock option grants on January 28, 2026 in connection with an Arrangement Agreement with XenoTherapeutics.
The common shares, including 18,800 underlying restricted stock units, and the options were exchanged for $2.20 in cash per share plus one non-transferable contingent value right (CVR) per share, with options receiving $2.20 less the applicable exercise price plus one CVR per underlying share. After these transactions, she reported holding zero common shares and zero derivative securities.
Pursuant to the Arrangement Agreement, Xeno Acquisition Corp. acquired all issued and outstanding Repare common shares on the same cash-and-CVR terms.